Celsion Corporation (CLSN) gains on positive data

Celsion Corporation CLSN shares rose 3% to $2.42 after the company reported ongoing positive data from its Phase 2 DIGNITY study in breast cancer. Share volume was 41,000, compared to an all-day average of 56,000